Sino Biological Inc. announced a CRO services partnership with Ainnocence Inc. of San Jose, California. Under the terms of this partnership, Sino Biological will add Ainnocence's cutting-edge artificial intelligence-based prediction technology to its current antibody development CRO services offering. The AI-based platform enables fast, efficient, and accurate prediction of antibody-antigen interaction, including binding affinity assessment.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
75.95 CNY | -0.37% | -0.73% | -7.83% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.83% | 1.35B | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- 301047 Stock
- News Sino Biological,Inc.
- Sino Biological and Ainnocence Partner to Offer Next-Generation CRO Antibody Development Services